Sphera Funds Management LTD. trimmed its holdings in shares of Pharvaris (NASDAQ:PHVS - Free Report) by 11.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 388,183 shares of the company's stock after selling 51,109 shares during the quarter. Pharvaris accounts for about 1.3% of Sphera Funds Management LTD.'s portfolio, making the stock its 24th largest position. Sphera Funds Management LTD. owned 0.74% of Pharvaris worth $7,441,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its holdings in shares of Pharvaris by 1,125.3% during the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock worth $59,000 after purchasing an additional 2,847 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of Pharvaris in the fourth quarter valued at about $64,000. Barclays PLC acquired a new stake in shares of Pharvaris in the third quarter valued at about $106,000. KLP Kapitalforvaltning AS bought a new position in shares of Pharvaris during the fourth quarter worth about $111,000. Finally, Point72 Asset Management L.P. acquired a new position in shares of Pharvaris in the fourth quarter worth approximately $152,000.
Pharvaris Stock Down 2.7%
NASDAQ:PHVS traded down $0.46 during trading hours on Wednesday, reaching $16.79. The company had a trading volume of 4,697 shares, compared to its average volume of 57,559. Pharvaris has a twelve month low of $11.51 and a twelve month high of $25.50. The firm has a market cap of $877.95 million, a price-to-earnings ratio of -6.00 and a beta of -2.85. The business's 50-day simple moving average is $15.40 and its two-hundred day simple moving average is $17.52.
Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.09). As a group, equities analysts predict that Pharvaris will post -2.71 earnings per share for the current year.
Analyst Ratings Changes
A number of equities analysts recently weighed in on the stock. Cantor Fitzgerald lowered their target price on shares of Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a research note on Wednesday, May 14th. JMP Securities boosted their price objective on Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a research note on Friday, January 31st.
View Our Latest Analysis on Pharvaris
Pharvaris Profile
(
Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Further Reading
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
